Şule Mine Bakanay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Şule Mine Bakanay has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Sema Akıncı
Department of Hematology, Ministry of Health Ankara City Hospital, Ankara, Turkey
4 shared publications - Aysun Senturk Yikilmaz
Department of Hematology, Denizli State Hospital, Denizli 20010, Türkiye
3 shared publications - Eren Gunduz
Department of Internal Medicine, Division of Hematology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir 26040, Turkey
2 shared publications - Funda Ceran
Department of Hematology, Ankara Bilkent City Hospital, Ankara 06800, Türkiye
2 shared publications - Imdat Dilek
Ankara City Hosp, Clin Hematol, Ankara, Turkey
2 shared publications - Mehmet Ali Uçar
Department of Hematology, Faculty of Medicine, Çukurova University, 01330 Adana, Türkiye
2 shared publications
Latest Publications
- Open Access
- 23 July 2025
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 42 (3) , 203-212
Clinical Manifestations, Treatment Characteristics and Clinical Outcome in Patients with Acquired Thrombotic Thrombocytopenic Purpura (aTTP) in the Real-World Setting: An Interim Analysis of the Turkish aTTP Registry
This study aimed to investigate the clinical manifestations, treatment patterns and clinical outcomes in patients with iTTP across Türkiye via an interim analysis of the Turkish iTTP registry. A total of 215 patients with iTTP (median age at diagnosis 41 years, 58.6% female) diagnosed between 2001 and 2023 were retrospectively analyzed in the interim analysis of the prospective noninterventional observational multicenter iTTP registry study conducted at 19 tertiary hematology centers. Data on patient demographics, disease characteristics on initial admission, treatment characteristics, and responses, exacerbations/relapses, and the survival outcome were registered via electronic case report forms. Infection (15.0%), new drug initiation (9.7%), and pregnancy/postpartum (6.3%) within 3 weeks before diagnosis were the most prevalent potential triggers. Patients presented more commonly with systemic/constitutional (fatigue 68.8%; fever 18.1%) and neurologic (headache 40.0%, vertigo 32.1%), followed by hemorrhagic, gastrointestinal, renal, and cardiovascular manifestations. Based on the PLASMIC risk scoring, 77.8% of patients were initially at high risk for TTP. The initial treatment was commenced within the first 48 hours of hospital admission in 64.1% of patients (36.2% on the day of admission). Treatment was mainly based on TPE exchange (92.1%) and steroids (63.7%), while rituximab was used in 15.8% of patients. The clinical response rate was 79.9%, and clinical remission was achieved in 68.2% of patients. As for the ADAMTS13 levels, partial and complete responses were achieved in 17.7% and 14.6%, respectively. During a median of 30 months (range, 0.1 to 262.4 months) follow-up, 35 patients experienced exacerbations/relapses. Mortality occurred in 11 (5.5%) patients and was found to be disease-related in 6 (3.0%). This interim analysis of the nationwide Turkish iTTP registry study provided valuable data on the real-world clinical practice in the diagnosis and management of iTTP at different hematology clinics across the country.
- 23 July 2025
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 42 (3) , 203-212
Open AccessClinical Manifestations, Treatment Characteristics and Clinical Outcome in Patients with Acquired Thrombotic Thrombocytopenic Purpura (aTTP) in the Real-World Setting: An Interim Analysis of the Turkish aTTP Registry
This study aimed to investigate the clinical manifestations, treatment patterns and clinical outcomes in patients with iTTP across Türkiye via an interim analysis of the Turkish iTTP registry. A total of 215 patients with iTTP (median age at diagnosis 41 years, 58.6% female) diagnosed between 2001 and 2023 were retrospectively analyzed in the interim analysis of the prospective noninterventional observational multicenter iTTP registry study conducted at 19 tertiary hematology centers. Data on patient demographics, disease characteristics on initial admission, treatment characteristics, and responses, exacerbations/relapses, and the survival outcome were registered via electronic case report forms. Infection (15.0%), new drug initiation (9.7%), and pregnancy/postpartum (6.3%) within 3 weeks before diagnosis were the most prevalent potential triggers. Patients presented more commonly with systemic/constitutional (fatigue 68.8%; fever 18.1%) and neurologic (headache 40.0%, vertigo 32.1%), followed by hemorrhagic, gastrointestinal, renal, and cardiovascular manifestations. Based on the PLASMIC risk scoring, 77.8% of patients were initially at high risk for TTP. The initial treatment was commenced within the first 48 hours of hospital admission in 64.1% of patients (36.2% on the day of admission). Treatment was mainly based on TPE exchange (92.1%) and steroids (63.7%), while rituximab was used in 15.8% of patients. The clinical response rate was 79.9%, and clinical remission was achieved in 68.2% of patients. As for the ADAMTS13 levels, partial and complete responses were achieved in 17.7% and 14.6%, respectively. During a median of 30 months (range, 0.1 to 262.4 months) follow-up, 35 patients experienced exacerbations/relapses. Mortality occurred in 11 (5.5%) patients and was found to be disease-related in 6 (3.0%). This interim analysis of the nationwide Turkish iTTP registry study provided valuable data on the real-world clinical practice in the diagnosis and management of iTTP at different hematology clinics across the country.
- Open Access
- 18 February 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (1) , 203-208
Does CD47 expression have prognostic significance in classical Hodgkin lymphoma?
Background/aimHodgkin Lymphoma (HL) is highly treatable, but new chemotherapy agents are needed for patients with progression or recurrence. CD47 regulates anti-phagocytic activity by signaling through the SIRPα (signal regulatory protein alpha) pathway on macrophages. This study aims to assess the expression of CD47 in HL cases and explore its relationship with Epstein-Barr Virus (EBV) status and the International Prognostic Index (IPI).Materials and Methods120 patients diagnosed with Classical HL, characterized by the presence of Hodgkin and Reed-Sternberg (HRS) cells, for whom IPI scores were available. Demographic data and EBV status were retrieved from hospital records. CD47 immunohistochemical expression in HRS cells was evaluated based on its prevalence and intensity. The product of these two values was used to calculate the CD47 expression score.ResultsOf the 120 cases, 76 (63.33%) were male and 44 (36.66%) were female, with an average age of 38.77 years. EBV ISH test results were available for 93 cases, of which 48 (51.61%) were positive. CD47 expression was 67% on average, and cases were categorized based on CD47 expression scores of ≤6 and >6 and IPI scores of ≤2 and >2. No significant relationship was found between CD47 expression score and age(p:0,990), gender(p: 0.086), EBV status(p: 0.374), or IPI score(p: 0.805). However, higher IPI scores were significantly associated with increased EBV positivity (p: 0.041).ConclusionCD47 was widely expressed, but no significant relationship with clinical parameters was observed. Further studies are required to validate its role as a biomarker.
- 18 February 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (1) , 203-208
Open AccessDoes CD47 expression have prognostic significance in classical Hodgkin lymphoma?
Background/aimHodgkin Lymphoma (HL) is highly treatable, but new chemotherapy agents are needed for patients with progression or recurrence. CD47 regulates anti-phagocytic activity by signaling through the SIRPα (signal regulatory protein alpha) pathway on macrophages. This study aims to assess the expression of CD47 in HL cases and explore its relationship with Epstein-Barr Virus (EBV) status and the International Prognostic Index (IPI).Materials and Methods120 patients diagnosed with Classical HL, characterized by the presence of Hodgkin and Reed-Sternberg (HRS) cells, for whom IPI scores were available. Demographic data and EBV status were retrieved from hospital records. CD47 immunohistochemical expression in HRS cells was evaluated based on its prevalence and intensity. The product of these two values was used to calculate the CD47 expression score.ResultsOf the 120 cases, 76 (63.33%) were male and 44 (36.66%) were female, with an average age of 38.77 years. EBV ISH test results were available for 93 cases, of which 48 (51.61%) were positive. CD47 expression was 67% on average, and cases were categorized based on CD47 expression scores of ≤6 and >6 and IPI scores of ≤2 and >2. No significant relationship was found between CD47 expression score and age(p:0,990), gender(p: 0.086), EBV status(p: 0.374), or IPI score(p: 0.805). However, higher IPI scores were significantly associated with increased EBV positivity (p: 0.041).ConclusionCD47 was widely expressed, but no significant relationship with clinical parameters was observed. Further studies are required to validate its role as a biomarker.
- Open Access
- 31 December 2023
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 4 (6) , 619-624
Comparison of low dose cytosine arabinoside, azacitidine and azacitidine venetoclax combination treatment as remission induction in elderly acute myeloid leukemia patients
Aims: Low-intensity therapies are widely preferred in the treatment of advanced age, fragile acute myeloid leukemia (AML) patients. In this study, we aimed to compare hematological recovery rates after first cycle chemotherapy and overall survival for advanced aged AML patients treated with azacitidine (AZA) or low dose cytosine arabinoside (LDCA) or venetoclax (Ven) with AZA combination. Methods: Ninety-one patients were retrospectively analyzed. Results: Forty-one patients treated with LDCA, 30 patients treated with AZA and 20 patients treated with AZA+Ven were included in the study. Patients who received these three treatments and who achieved response and did not receive any other treatment during the follow-up period were included in the study. Median age at diagnosis was 70. The percentage of patients who achieved neutrophil recovery after the first cycle was 27%, 73% and 50% of the patients treated with LDCA, AZA and AZA+Ven respectively. The rate of patients who achieved platelet recovery was 60%, 80%, 70% respectively. Erythrocyte transfusion independency was 54% for LDCA patients, 73% for AZA patients and 60% for combination therapy. Overall survival was longer in patients receiving AZA+Ven than other treatment groups while grade 3-4 infections were more common in the first cycle of the treatment. Conclusion: According to our study, patients treated with AZA had better platelet and neutrophil recovery rates with also longer overall survival than patients treated with LDCA, but total overall survival was superior in AZA+Ven combination. Hypomethylating agents with venetoclax is a preferable treatment option in elderly AML patients.
- 31 December 2023
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 4 (6) , 619-624
Open AccessComparison of low dose cytosine arabinoside, azacitidine and azacitidine venetoclax combination treatment as remission induction in elderly acute myeloid leukemia patients
Aims: Low-intensity therapies are widely preferred in the treatment of advanced age, fragile acute myeloid leukemia (AML) patients. In this study, we aimed to compare hematological recovery rates after first cycle chemotherapy and overall survival for advanced aged AML patients treated with azacitidine (AZA) or low dose cytosine arabinoside (LDCA) or venetoclax (Ven) with AZA combination. Methods: Ninety-one patients were retrospectively analyzed. Results: Forty-one patients treated with LDCA, 30 patients treated with AZA and 20 patients treated with AZA+Ven were included in the study. Patients who received these three treatments and who achieved response and did not receive any other treatment during the follow-up period were included in the study. Median age at diagnosis was 70. The percentage of patients who achieved neutrophil recovery after the first cycle was 27%, 73% and 50% of the patients treated with LDCA, AZA and AZA+Ven respectively. The rate of patients who achieved platelet recovery was 60%, 80%, 70% respectively. Erythrocyte transfusion independency was 54% for LDCA patients, 73% for AZA patients and 60% for combination therapy. Overall survival was longer in patients receiving AZA+Ven than other treatment groups while grade 3-4 infections were more common in the first cycle of the treatment. Conclusion: According to our study, patients treated with AZA had better platelet and neutrophil recovery rates with also longer overall survival than patients treated with LDCA, but total overall survival was superior in AZA+Ven combination. Hypomethylating agents with venetoclax is a preferable treatment option in elderly AML patients.
- Open Access
- 25 August 2022
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 39 (3) , 196-203
Leukemia: Reduction Ratio and Halving Time of BCR: : ABL1 IS Transcript Levels
Objective: Achieving an early molecular response (EMR) is crucial for improving the prognosis of patients with chronic myeloid leukemia (CML). The halving time (HT) and reduction ratio (RR) of BCR::ABL1 transcript levels have recently emerged as additional prognostic indexes besides the BCRABL1 International Scale (IS). We aimed to investigate the prognostic role of BeR:ABL1 transcript levels, HT, and RR on molecular response kinetics at 3 months in patients with newly diagnosed chronic-phase (CP)-CML. Materials and Methods: Forty patients with CP-CML who received first-line imatinib treatment were included in this study. BCR::ABL1 transcript levels and molecular responses at baseline and at 3, 6, 12, and 24 months of treatment were evaluated retrospectively. Major molecular response (MMR) at 12 months and event-free survival (EFS) were determined as primary endpoints and the effects of treatment kinetics on these parameters were examined. Results: Of the 40 patients, BCR:ABL1 IS was <= 10% at 3 months in 72.5%, representing EMR. The rate of event occurrence was 45.50/u in patients with BCR:ABL1 IS of >10%, whereas it was 6.9% in those with BCRABL1 IS of 10% (p=0.004). MMR was detected in 62.1% of the patients with EMR and in 9.1% of those without EMR (p=0.003). The cut-off value for achieving MMR was 24 days for HT and 0.04 for RR. Deep molecular response (DMR) at 24 months was associated with HT of 24 days and RR of 0.04. EFS was found to be significantly better in the group with BCRABL1 IS of 100/c) and HT of 24 days (p=0.001) and in the group with BCRABL1 IS of <= 10% and RR of < 0.04 (p=0.007) compared to others. Conclusion: Our findings revealed that MMR could be predicted via EMR as well as by HT and RR. Additionally, HT of 24 days and RR of <= 0.04 were more important than BCR::ABL1 IS of <= 10% in achieving DMR at 24 months, and the combination of BCRABL1 IS of <= 10% with both HI of <= 24 days and RR of <= 0.04 has the best predictive value for EFS.
- 25 August 2022
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 39 (3) , 196-203
Open AccessLeukemia: Reduction Ratio and Halving Time of BCR: : ABL1 IS Transcript Levels
Objective: Achieving an early molecular response (EMR) is crucial for improving the prognosis of patients with chronic myeloid leukemia (CML). The halving time (HT) and reduction ratio (RR) of BCR::ABL1 transcript levels have recently emerged as additional prognostic indexes besides the BCRABL1 International Scale (IS). We aimed to investigate the prognostic role of BeR:ABL1 transcript levels, HT, and RR on molecular response kinetics at 3 months in patients with newly diagnosed chronic-phase (CP)-CML. Materials and Methods: Forty patients with CP-CML who received first-line imatinib treatment were included in this study. BCR::ABL1 transcript levels and molecular responses at baseline and at 3, 6, 12, and 24 months of treatment were evaluated retrospectively. Major molecular response (MMR) at 12 months and event-free survival (EFS) were determined as primary endpoints and the effects of treatment kinetics on these parameters were examined. Results: Of the 40 patients, BCR:ABL1 IS was <= 10% at 3 months in 72.5%, representing EMR. The rate of event occurrence was 45.50/u in patients with BCR:ABL1 IS of >10%, whereas it was 6.9% in those with BCRABL1 IS of 10% (p=0.004). MMR was detected in 62.1% of the patients with EMR and in 9.1% of those without EMR (p=0.003). The cut-off value for achieving MMR was 24 days for HT and 0.04 for RR. Deep molecular response (DMR) at 24 months was associated with HT of 24 days and RR of 0.04. EFS was found to be significantly better in the group with BCRABL1 IS of 100/c) and HT of 24 days (p=0.001) and in the group with BCRABL1 IS of <= 10% and RR of < 0.04 (p=0.007) compared to others. Conclusion: Our findings revealed that MMR could be predicted via EMR as well as by HT and RR. Additionally, HT of 24 days and RR of <= 0.04 were more important than BCR::ABL1 IS of <= 10% in achieving DMR at 24 months, and the combination of BCRABL1 IS of <= 10% with both HI of <= 24 days and RR of <= 0.04 has the best predictive value for EFS.
- Open Access
- 1 January 2021
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 38 (4) , 314-320
A Rare Lymphoproliferative Disease: Castleman Disease
Castleman disease is a rare lymphoproliferative disease also known as angiofollicular lymph node hyperplasia. It is classified as hyaline vascular and plasmacytic variants histologically but characteristics of both types can coexist. Most unicentric cases of the disease are hyaline vascular while most multicentric cases are of the plasmacytic type. Although the pathogenesis is not completely understood, the role of interleukin (IL)-6 in unicentric disease and the roles of IL-6 and human herpes virus-8 in multicentric disease are well defined. Unicentric disease is typically localized and symptoms are minimal and treated locally. Multicentric disease is systemic and clinically characterized by generalized lymphadenopathy, splenomegaly, anemia, and systemic inflammatory symptoms. Systemic therapies are primarily given. Several malignant diseases including lymphomas, POEMS syndrome, follicular dendritic cell sarcomas, paraneoplastic pemphigus, Kaposi sarcoma, and amyloidosis can be associated with Castleman disease. In this paper, recent information about Castleman disease, which is a rare disease, is summarized.
- 1 January 2021
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 38 (4) , 314-320
Open AccessA Rare Lymphoproliferative Disease: Castleman Disease
Castleman disease is a rare lymphoproliferative disease also known as angiofollicular lymph node hyperplasia. It is classified as hyaline vascular and plasmacytic variants histologically but characteristics of both types can coexist. Most unicentric cases of the disease are hyaline vascular while most multicentric cases are of the plasmacytic type. Although the pathogenesis is not completely understood, the role of interleukin (IL)-6 in unicentric disease and the roles of IL-6 and human herpes virus-8 in multicentric disease are well defined. Unicentric disease is typically localized and symptoms are minimal and treated locally. Multicentric disease is systemic and clinically characterized by generalized lymphadenopathy, splenomegaly, anemia, and systemic inflammatory symptoms. Systemic therapies are primarily given. Several malignant diseases including lymphomas, POEMS syndrome, follicular dendritic cell sarcomas, paraneoplastic pemphigus, Kaposi sarcoma, and amyloidosis can be associated with Castleman disease. In this paper, recent information about Castleman disease, which is a rare disease, is summarized.
- 1 July 2020
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 20 (7) , e375-e381
The Triple Positivity for EBV, PD-1, and PD-L1 Identifies a Very High Risk Classical Hodgkin Lymphoma
- 1 July 2020
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 20 (7) , e375-e381
The Triple Positivity for EBV, PD-1, and PD-L1 Identifies a Very High Risk Classical Hodgkin Lymphoma
- 15 January 2019
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 3 (1) , 4-8
Effect of Treatment on the Muscle Mass and Response to Therapy in Hodgkin’s Lymphoma
- 15 January 2019
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 3 (1) , 4-8
Effect of Treatment on the Muscle Mass and Response to Therapy in Hodgkin’s Lymphoma